Coherus Oncology, Inc. (CHRS) 股票分析

公司概述

Coherus Oncology, Inc. operates within the healthcare sector as a biotechnology entity, focusing on the research, development, and commercialization of immunotherapies designed to treat cancer in the United States. The company's core product portfolio includes UDENYCA, which serves as a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, alongside LOQTORZI, a novel next-generation program. In terms of operational scale, the firm employs 147 individuals and maintains a market capitalization of $247.32M. With an annual revenue of $42.17M, the company operates as a mid-cap biopharmaceutical entity with significant growth potential, yet the high price-to-sales ratio of 5.86 relative to its modest revenue base indicates that the market values its future pipeline assets at a premium that far exceeds current earnings generation capabilities.

财务健康

The company reported a revenue of $42.17M over the trailing twelve months, yet this figure masks a net income of $-183,124,000 and an EBITDA of $-172,510,000, revealing a cost structure where expenses significantly outpace top-line generation. Consequently, the free cash flow stands at $-68,722,872, indicating that the company is currently burning cash to fund its R&D and commercialization efforts rather than generating liquidity for shareholders. The gross margin is reported at 67.2%, which suggests efficient production costs for its biosimilar products, whereas the operating margin of -339.5% and profit margin of 398.4% highlight the substantial non-operating costs or specific accounting adjustments impacting the bottom line. Regarding balance sheet leverage, the firm holds $172.12M in cash against $54.36M in debt, supported by a current ratio of 1.47, which indicates a robust short-term liquidity position capable of covering obligations. However, the debt-to-equity ratio of 89.10 suggests a capital structure heavily reliant on equity financing given the absence of traditional leverage, while the return on equity and return on assets are effectively N/A or negative due to the lack of positive net income.

估值评估

Valuation metrics for Coherus present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -2.04, implying that the market is pricing the stock based on future earnings expectations that are currently negative. The price-to-book ratio of 3.27 indicates that the company is trading at a significant premium over its tangible book value, reflecting investor confidence in its intangible assets and drug pipeline. Alternative valuation measures such as the price-to-sales ratio of 5.86 and an EV/EBITDA of -0.75 further suggest that the stock is valued based on revenue multiples rather than cash flow profitability. In terms of trading range, the stock has fluctuated between a 52-week low of $0.71 and a 52-week high of $2.62, meaning the current price sits well below the recent peak, though the exact percentage deviation requires the current price input which is not explicitly provided in the source facts. The stock exhibits a beta of 1.04, suggesting that its price volatility moves in tandem with, or slightly exceeds, the broader market movements, characteristic of small-cap biotechnology firms.

Growth & Income

Revenue growth has accelerated significantly with a year-over-year increase of 64.9%, while earnings growth is listed as N/A due to the company's persistent net losses. Since the earnings growth metric is unavailable, it is impossible to determine if earnings are growing faster or slower than revenue in a traditional sense, but the widening gap between the $42.17M revenue and the negative $-183,124,000 net income implies that top-line expansion has not yet translated into profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available capital and reserves into research and development rather than distributing income to shareholders. This financial profile characterizes Coherus as a high-risk, high-reward growth stock where the primary driver of value is the successful commercialization of its immunotherapy programs rather than current income generation or dividend stability.